Full Name
Beth Faiman PhD, MSN, APN-BC, TCTCN, AOCN, FAAN, FAPO
Job Title
Adult Nurse Practitioner
Institution/Organization
Cleveland Clinic Taussig Cancer Institute, Department of Hematology and Medical Oncology
Speaker Bio
Dr Beth Faiman is an adult nurse practitioner in the Department of Hematology/Oncology at the Cleveland Clinic. She is also a clinical member of the Case Comprehensive Cancer Center and editor-in-chief of the Journal of the Advanced Practitioner in Oncology. Additionally, she is the editor of several books and the author of numerous chapters and papers. In 2013, Dr Faiman served as co-chair of the first Nursing Symposium at the International Myeloma Workshop and subsequent conferences. Her leadership and mentorship have been recognized with multiple national honors. Dr Faiman was inducted as an Advanced Practice in Oncology fellow and as a distinguished fellow of the American Academy of Nursing. She remains an active author, presenter, mentor, and educator in hematology, oncology, cellular therapies, and supportive cancer care.
Speaking At
Start With FIRST-LINE BESREMi Pen for Patients With PV Requiring Cytoreductive Therapy: From Clinical Results to Real-World PracticeStart With FIRST-LINE BESREMi Pen for PV: Disease Alteration That Supports Sustained Control
Start With FIRST-LINE BESREMi Pen for Patients With PV Requiring Cytoreductive Therapy: From Clinical Results to Real-World Practice
Start With FIRST-LINE BESREMi Pen for Patients With PV Requiring Cytoreductive Therapy: From Clinical Results to Real-World PracticeStart With FIRST-LINE BESREMi Pen for PV: Disease Alteration That Supports Sustained Control
Start With FIRST-Start With FIRST-LINE BESREMi Pen for Patients With PV Requiring Cytoreductive Therapy: From Clinical Results to Real-World PracticeLINE BESREMi Pen for PV: Disease Alteration That Supports Sustained Control
Start With FIRST-LINE BESREMi Pen for Patients With PV Requiring Cytoreductive Therapy: From Clinical Results to Real-World Practice
Start With FIRST-LINE BESREMi Pen for Patients With PV Requiring Cytoreductive Therapy: From Clinical Results to Real-World PracticeStart With FIRST-LINE BESREMi Pen for PV: Disease Alteration That Supports Sustained Control
Start With FIRST-Start With FIRST-LINE BESREMi Pen for Patients With PV Requiring Cytoreductive Therapy: From Clinical Results to Real-World PracticeLINE BESREMi Pen for PV: Disease Alteration That Supports Sustained Control
